Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [3] - The company has a wholly owned clinical stage pipeline that includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) [3] - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - The partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, with collaborations involving Gilead Sciences, Sanofi, and Pfizer [3] Upcoming Events - Hans van Houte, CFO, and Jason Kantor, Ph.D., CBO of Nurix will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 2:05 p.m. ET [1] - The fireside chat will be webcast live and archived for 30 days post-event [2]